Applying a research ethics committee approach to a medical practice controversy: The case of the selective COX-2 inhibitor rofecoxib

Journal of Medical Ethics

Volumn 30, Issue 2, 2004, Pages 182-184

  James, Michael J ^a   Cleland, L G ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG CLASSIFICATION; DRUG MARKETING; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GENERAL PRACTITIONER; HEART INFARCTION; HUMAN; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICOLEGAL ASPECT; PATIENT CARE; PATIENT INFORMATION; PRACTICE GUIDELINE; PRESCRIPTION; PROFESSIONAL STANDARD; PUBLICATION; RESEARCH ETHICS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; THROMBOSIS;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DRUG INDUSTRY; ETHICS COMMITTEES, RESEARCH; HUMANS; INFORMED CONSENT; LACTONES; MARKETING; PROFESSIONAL PRACTICE; PUBLISHING; SULFONES;

EID: 2342420408     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2003.004515     Document Type: Article

References (18)

1. Merck & Co. Annual report, 2002. www.merck.com/finance/annualreport/ar2002/ (accessed 13 Feb 2004).
2. Lexchin J. Should doctors be prescribing new drugs? Int J Risk Safety Med 2002;15:213-22.
3. CBC disclosure: targeting doctors. www.cbc.ca/disclosure/archives/0103_pharm/resources.html (accessed 13 Feb 2004).
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
5. US Food and Drug Authority. FDA advisory committee briefing document NDA 21-042, s007. VIOXX gastrointestinal safety, 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_03_med.pdf (accessed 13 Feb 2004).
6. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
7. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
8. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.
9. Ray WA, Stein CM, Dougherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
10. Hochberg MC. COX-2: Where are we in 2003? Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients. Arthritis Res Ther 2003;5:28-31.
11. Caughey GE, Cleland LG, Penglis PS, et al. Roles of cyclooxygenase (COX)-1 and -2 in prostanoid production by human endothelial cells: selective upregulation of prostacyclin synthesis by COX-2. J Immunol 2001;167:2831-8.
12. 2. J Biol Chem 2001;276:37839-45.
13. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-7.
14. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-41.
15. 2. Science 2002; 296:539-41.
16. Sidaway v Governors of Bethlem Royal Hospital (1985; AC 871).
17. Rogers v Whittaker (1992; 175 CLR 479).
18. Cleland LG, James MJ, Stamp LK, et al. COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 2001;175:214-7.